# MAGENTA (NCT03081910)

> Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

No report yet. It can be ordered.

- Indication: T-cell malignancies expressing CD5 antigen

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03081910
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Baylor College of Medicine
- Conditions: T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma; T-cell Acute Lymphoblastic Leukemia
- Interventions: Autologous CD5.CAR/28zeta CAR T cells; Allogeneic CD5.CAR/28zeta CAR T cells
- Enrollment: 104
- Primary outcome: Dose limiting toxicity (DLT) rate

## Indexed commentary on MAGENTA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=magenta-nct03081910